SELLAS to Host Conference Call Following Oral Presentation of Phase 2b Results of NeuVax™ + Herceptin® to Prevent Breast C...
October 15 2018 - 8:30AM
Interim and Updated Final Clinical Data
to be Presented
SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the
“Company”), a clinical-stage biopharmaceutical company focused on
the development of novel cancer immunotherapies for a broad range
of cancer indications, today announced that it will host a
conference call at 8:00 a.m. ET on October 22, 2018, following the
oral presentation at the ESMO 2018 Annual Meeting of the interim
(median follow-up of 18.8 months) and updated and final (median
follow-up of 26.1 months) clinical data from its Phase 2b trial of
the combination of trastuzumab (Herceptin
®) +/-
nelipepimut-S (NeuVax
™) targeting HER2
low-expressing breast cancer patient cohorts. Management and
invited Key Opinion Leaders, including Dr. Elizabeth Mittendorf,
MD, PhD and Dr. George Peoples, MD, FACS, will participate in the
conference call.
Conference Call Details for Monday, October 22, 2018 at
8:00 a.m. ET:
To participate in the conference call, please dial (866)
416-7995 (domestic) or +1 (409) 217-8225 (international) and refer
to conference ID 5571389. A live webcast of the call can be
accessed under "Events & Presentations" in the Investors
section of the Company's website at www.sellaslifesciences.com.
An archived webcast recording will be available on the SELLAS
website beginning approximately two hours after the call.
Details for the ESMO presentation are as follows:
Title: Pre-specified interim analysis of a
randomized phase 2b trial of trastuzumab + nelipepimut-S
(NeuVax™) vs trastuzumab for the prevention of
recurrence demonstrates benefit in triple negative (HER2
low-expressing) breast cancer patientsDate and
Time: 22 October, 2018; 11:54 am Central European Time
(5:54 am ET)Location: Hall A2 - Room 18; Messe
Munich Congress Venue, Munich, Germany
Herceptin® is a registered trademark of Genentech, Inc. and is
not a trademark of SELLAS. The manufacturer of this brand is not
affiliated with and does not endorse SELLAS or its products.
About ESMO
The European Society for Medical Oncology (ESMO) is Europe’s
leading non-profit medical oncology organization. ESMO is a
membership-based society, comprising of 500 expert committee
members and 18,000 oncology professionals. ESMO organizes a large
number of meetings to provide its members and the community with
the resources they need and also plays a major role in public
policy and European affairs. The ESMO 2018 Annual Meeting
represents a multi-professional platform for oncology education and
exchange, and for immense international visibility for scientific
research, and will be held under the tagline “Securing access to
optimal cancer care.”
About SELLAS Life Sciences Group, Inc.
SELLAS is a clinical-stage biopharmaceutical company focused on
novel cancer immunotherapeutics for a broad range of cancer
indications. SELLAS’ lead product candidate, galinpepimut-S (GPS),
is licensed from Memorial Sloan Kettering Cancer Center and targets
the Wilms Tumor 1 (WT1) protein, which is present in an array of
tumor types. GPS has potential as a monotherapy or in
combination to address a broad spectrum of hematologic malignancies
and solid tumor indications. SELLAS has Phase 3 clinical
trials planned (pending funding availability) for GPS in two
indications, acute myeloid leukemia (AML) and malignant pleural
mesothelioma (MPM), and is also developing GPS as a potential
treatment for multiple myeloma (MM) and ovarian cancer.
SELLAS plans to study GPS in up to four additional
indications. SELLAS has received Orphan Drug designations for
GPS from both the U.S. Food & Drug Administration (FDA) and
European Medicines Agency (EMA) for AML, MPM, and MM; GPS also
received Fast Track designation for AML and MPM from the FDA.
SELLAS’ second product candidate, NeuVax™ (nelipepimut-S), is a
HER2-directed cancer immunotherapy being investigated for the
prevention of the recurrence of breast cancer after standard of
care treatment in the adjuvant setting. NeuVax™ has received Fast
Track status designation by FDA for the treatment of patients with
early stage breast cancer with low to intermediate HER2 expression,
otherwise known as HER2 1+ or 2+, following standard of care.
For more information on SELLAS, please visit
www.sellaslifesciences.com.
Investor Contacts:Will O’ConnorStern Investor
Relations, Inc.212-362-1200ir@sellaslife.com
David Moser, JDSellas Life Sciences
Group813-864-2571info@sellaslife.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2023 to Sep 2024